|
1
|
Bosetti C, Bertuccio P, Negri E, La
Vecchia C, Zeegers MP and Boffetta P: Pancreatic cancer: Overview
of descriptive epidemiology. Mol Carcinog. 51:3–13. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ashour AA, Gurbuz N, Alpay SN, AbdelAziz
AA, Mansour AM, Huo L and Ozpolat B: Elongation factor-2 kinase
regulates TG2/β1 integrin/Src/uPAR pathway and
epithelial-mesenchymal transition mediating pancreatic cancer cells
invasion. J Cell Mol Med. 18:2235–2251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dores GM, Curtis RE, van Leeuwen FE,
Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH,
Hodgson DC, et al: Pancreatic cancer risk after treatment for
Hodgkin lymphoma. Ann Oncol. 25:2073–2079. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cui J, Jiang W, Wang S, Wang L and Xie K:
Role of Wnt/β-catenin signaling in drug resistance of pancreatic
cancer. Curr Pharm Des. 18:2464–2471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kyuno D, Yamaguchi H, Ito T, Kono T,
Kimura Y, Imamura M, Konno T, Hirata K, Sawada N and Kojima T:
Targeting tight junctions during epithelial to mesenchymal
transition in human pancreatic cancer. World J Gastroenterol.
20:10813–10824. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao J, Wang S, Gunther LK, Kitajiri SI, Li
C and Sakamoto T: The actin-bundling protein TRIOBP-4 and -5
promotes the motility of pancreatic cancer cells. Cancer Lett.
356:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z and Ma Q: Beta-catenin is a
promising key factor in the SDF-1/CXCR4 axis on metastasis of
pancreatic cancer. Med Hypotheses. 69:816–820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Voltz JW, Brush M, Sikes S, Steplock D,
Weinman EJ and Shenolikar S: Phosphorylation of PDZ1 domain
attenuates NHERF-1 binding to cellular targets. J Biol Chem.
282:33879–33887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs SY, Ougolkov AV, Spiegelman VS and
Minamoto T: Oncogenic beta-catenin signaling networks in colorectal
cancer. Cell Cycle. 4:1522–1539. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Georgescu MM, Morales FC, Molina JR and
Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med.
8:459–468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ji M, Yuan L, Lv X, Dong W and Peng X:
EBP50 regulates the apoptosis of pancreatic cancer cells by
decreasing the expression levels of Bcl-2. Exp Ther Med. 8:919–924.
2014.PubMed/NCBI
|
|
12
|
Lv XG, Ji MY, Dong WG, Lei XF, Liu M, Guo
XF, Wang J and Fang C: EBP50 gene transfection promotes
5-fluorouracil-induced apoptosis in gastric cancer cells through
Bax- and Bcl-2-triggered mitochondrial pathways. Mol Med Rep.
5:1220–1226. 2012.PubMed/NCBI
|
|
13
|
Ji MY, Fan DK, Lv XG, Peng XL, Lei XF and
Dong WG: The detection of EBP50 expression using quantum dot
immunohistochemistry in pancreatic cancer tissue and down-regulated
EBP50 effect on PC-2 cells. J Mol Histol. 43:517–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun C, Zheng J, Cheng S, Feng D and He J:
EBP50 phosphorylation by Cdc2/Cyclin B kinase affects actin
cytoskeleton reorganization and regulates functions of human breast
cancer cell line MDA-MB-231. Mol Cells. 36:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cardone RA, Greco MR, Capulli M, Weinman
EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B,
Dell'Aquila ME, et al: NHERF1 acts as a molecular switch to program
metastatic behavior and organotropism via its PDZ domains. Mol Biol
Cell. 23:2028–2040. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Georgescu MM, Cote G, Agarwal NK and White
CL III: NHERF1/EBP50 controls morphogenesis of 3D colonic glands by
stabilizing PTEN and ezrin-radixin-moesin proteins at the apical
membrane. Neoplasia. 16:365.e1-e2–374.e1-e2. 2014. View Article : Google Scholar
|
|
18
|
Guo G, Yao G, Zhan G, Hu Y, Yue M, Cheng
L, Liu Y, Ye Q, Qing G, Zhang Y and Liu H: N-methylhemeanthidine
chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic
cancer cell proliferation via down-regulating AKT activation.
Toxicol Appl Pharmacol. 280:475–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bellizzi A, Malfettone A, Cardone RA and
Mangia A: NHERF1/EBP50 in breast cancer: Clinical perspectives.
Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun GY, Wu JX, Wu JS, Pan YT and Jin R:
Caveolin-1, E-cadherin and β-catenin in gastric carcinoma,
precancerous tissues and chronic non-atrophic gastritis. Chin J
Cancer Res. 24:23–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kreimann EL, Morales FC, de Orbeta-Cruz J,
Takahashi Y, Adams H, Liu TJ, McCrea PD and Georgescu MM: Cortical
stabilization of beta-catenin contributes to NHERF1/EBP50 tumor
suppressor function. Oncogene. 26:5290–5299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cornez I and Taskén K: Spatiotemporal
control of cyclic AMP immunomodulation through the PKA-Csk
inhibitory pathway is achieved by anchoring to an Ezrin-EBP50-PAG
scaffold in effector T cells. FEBS Lett. 584:2681–2688. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lazar CS, Cresson CM, Lauffenburger DA and
Gill GN: The Na+/H+ exchanger regulatory factor stabilizes
epidermal growth factor receptors at the cell surface. Mol Biol
Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI
|
